Sun Pharma Agrees to MFN Drug Pricing In US To Delay Tariffs On Innovative Medicines
Sun Pharmaceutical Industries has entered into an agreement with the US government to provide most favoured nation (MFN) drug pricing to state Medicaid programmes and future innovative medicine launches. In return, the company will receive a delay of more than two years on possible US tariffs affecting innovative pharmaceutical products. The agreement was announced during a White House signing…
We haven't written up this one. Free Press Journal has the full story — the link below goes straight to it.
